Foresee Pharmaceuticals Management
Management criteria checks 2/4
Foresee Pharmaceuticals' CEO is Ben Chien, appointed in Mar 2021, has a tenure of 12.17 years. directly owns 0.6% of the company’s shares, worth NT$77.15M. The average tenure of the management team and the board of directors is 4.4 years and 9 years respectively.
Key information
Ben Chien
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 4yrs |
| CEO ownership | 0.6% |
| Management average tenure | 4.4yrs |
| Board average tenure | 9yrs |
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -NT$931m |
| Jun 30 2024 | n/a | n/a | -NT$859m |
| Mar 31 2024 | n/a | n/a | -NT$977m |
| Dec 31 2023 | n/a | n/a | -NT$1b |
| Sep 30 2023 | n/a | n/a | -NT$906m |
| Jun 30 2023 | n/a | n/a | -NT$833m |
| Mar 31 2023 | n/a | n/a | -NT$530m |
| Dec 31 2022 | NT$16m | NT$12m | -NT$473m |
| Sep 30 2022 | n/a | n/a | -NT$458m |
| Jun 30 2022 | n/a | n/a | -NT$467m |
| Mar 31 2022 | n/a | n/a | -NT$532m |
| Dec 31 2021 | NT$12m | NT$10m | -NT$569m |
| Sep 30 2021 | n/a | n/a | -NT$429m |
| Jun 30 2021 | n/a | n/a | -NT$458m |
| Mar 31 2021 | n/a | n/a | -NT$560m |
| Dec 31 2020 | NT$8m | NT$8m | -NT$511m |
| Sep 30 2020 | n/a | n/a | -NT$546m |
| Jun 30 2020 | n/a | n/a | -NT$527m |
| Mar 31 2020 | n/a | n/a | -NT$556m |
| Dec 31 2019 | NT$12m | NT$7m | -NT$487m |
| Sep 30 2019 | n/a | n/a | -NT$568m |
| Jun 30 2019 | n/a | n/a | -NT$511m |
| Mar 31 2019 | n/a | n/a | -NT$489m |
| Dec 31 2018 | NT$9m | n/a | -NT$552m |
Compensation vs Market: Insufficient data to establish whether Ben's total compensation is reasonable compared to companies of similar size in the TW market.
Compensation vs Earnings: Ben's compensation has increased whilst the company is unprofitable.
CEO
Ben Chien
4yrs
Tenure
NT$16,166,000
Compensation
Dr. Benjamin Chien, also known as Ben, Ph.D. Founded Foresee Pharmaceuticals Co., Ltd. and serves as its Chairman. Dr. Chien served as President at Foresee Pharmaceuticals Co., Ltd.since March 25, 2021 un...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 4yrs | NT$16.17m | 0.60% NT$ 77.2m | |
| Co-founder & CTO | no data | NT$3.06m | 0.37% NT$ 48.0m | |
| COO & Chief Business Officer | no data | NT$585.00k | no data | |
| Chief Scientific Officer | 9.5yrs | NT$4.99m | 0.075% NT$ 9.7m | |
| Chief Medical Officer & Director | no data | NT$1.99m | 0.49% NT$ 63.5m | |
| Senior Vice President of Pharmaceutics & Manufacturing | 4.3yrs | NT$5.46m | 0.052% NT$ 6.7m | |
| Chief Financial Officer | 5.4yrs | no data | 0.19% NT$ 24.1m | |
| Accounting Officer | 1yr | no data | no data | |
| Consultant | 4.6yrs | no data | no data | |
| Consultant | 6.3yrs | no data | no data | |
| Senior Vice President of Clinical Development | 1.9yrs | no data | 0.045% NT$ 5.8m |
4.4yrs
Average Tenure
Experienced Management: 6576's management team is considered experienced (4.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 12.2yrs | NT$16.17m | 0.60% NT$ 77.2m | |
| Chief Medical Officer & Director | 12.2yrs | NT$1.99m | 0.49% NT$ 63.5m | |
| Director | 9.6yrs | NT$25.00k | 0.032% NT$ 4.1m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Representative Director | 12.2yrs | NT$35.00k | 0.062% NT$ 8.0m | |
| Independent Director | 9yrs | NT$440.00k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Director | 9yrs | NT$35.00k | 0.0084% NT$ 1.1m | |
| Independent Director | 6.8yrs | NT$440.00k | no data | |
| Independent Director | 9yrs | NT$440.00k | 0.073% NT$ 9.4m | |
| Independent Director | 1.8yrs | no data | no data |
9.0yrs
Average Tenure
Experienced Board: 6576's board of directors are considered experienced (9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/16 21:00 |
| End of Day Share Price | 2025/03/14 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Foresee Pharmaceuticals Co., Ltd. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | KGI Securities Co. Ltd. |
| Hsuan Chen | KGI Securities Co. Ltd. |
| Hengyu Fu | Masterlink Securities Corp. |